Praxis Precision Medicines Inc
PRAX
Get informed when a big investor buys or sells
+ FollowMarket Cap$6.87B
Close$
$15.87
95.1% downside
Current Fair Value
95.1% downsideOvervalued by 95.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $6.87 Billion |
|---|---|
| Enterprise Value | $6.34 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-13.48 |
| Beta | 2.76 |
| Outstanding Shares | 28,883,596 |
Return
| Return on Equity | -23.16% |
|---|---|
| Return on Assets | -22.36% |
| Return on Invested Capital | -25.31% |
Valuation & Multiples
| P/E Ratio | -24.27 |
|---|---|
| PEG | -72.29 |
| Price to Sales | - |
| Price to Book Ratio | 6.77 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -17.76 |
| Enterprise Value to Net Income | -20 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 13, 2026
EPS Estimate
$-3.60
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 3, 2026
EPS Estimate
$-3.66
Average shareholder expectationRevenue Estimate
$1.25 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 360.84% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.04%▼ 141.23% |
|---|---|
| Total Invested | $3.41M▼ 99.97% |
| Investors Holding | 5▼ 304.00% |
ESG Score
No data
About Praxis Precision Medicines Inc
2,020 employeesPraxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance. Praxis is applying in...